UCB reports bimekizumab response rates superior to Stelara in psoriasis

October 18, 2019
Treatment with bimekizumab, an interleukin-17A and IL-17F inhibitor in adults with chronic plaque psoriasis, resulted in at least a 90% improvement…

Meeting News

Bermekimab improves all disease measures of atopic dermatitis in phase 2 study

October 16, 2019
Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus…

Meeting News

Oral JAK inhibitor improves alopecia areata severity

October 15, 2019
Patients with moderate to severe alopecia areata who were assigned to CTP-543, an oral Janus kinase inhibitor from Concert Pharmaceuticals, achieved…

Meeting News

4-year data demonstrate safety, efficacy of Ilumya in plaque psoriasis

October 11, 2019
The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label…

Meeting News

Early diagnosis in systemic sclerosis key to limiting comorbidities

September 29, 2019
SAN DIEGO — Early screening and early diagnosis are critical to managing systemic sclerosis, according to a presentation at the 2019 Congress…

In the Journals

IBD risk increases with Enbrel therapy for other autoimmune diseases

July 18, 2019
Patients receiving Enbrel for inflammatory diseases other than inflammatory bowel disease have an increased risk for a diagnosis of Crohn’s…

Researchers pool experience to examine discoid lupus diagnosis, outcomes in children

July 8, 2019
Significant differences in perceived risk factors for systemic disease along with other substantial differences exist in screening and treating…

In the Journals

Glucocorticoid discontinuation plan recommended for juvenile-onset dermatomyositis

June 24, 2019
A group of international researchers writing in Pediatric Rheumatology have proposed a plan for tapering and discontinuing glucocorticoids in…

In the Journals

No conclusive evidence found on optimum antibiotic treatment for cellulitis

June 21, 2019
Researchers were unable to identify the most effective antibiotic treatment for cellulitis, as no one antibiotic was superior over another based on…

In the Journals

Hidradenitis suppurativa increases risk for alopecia

June 18, 2019
In a study investigating the relationship between hidradenitis suppurativa and alopecia areata in a U.S. sample, those with hidradenitis suppurativa…

In the Journals

Cyclosporine, methotrexate pose less risk for serious infections in atopic dermatitis

June 5, 2019
In adults with atopic dermatitis, treatment with cyclosporine or methotrexate appears to have a lower rate of serious infections than mycophenolate…

In the Journals

Researchers propose pathogenesis of acute inflammatory edema

June 5, 2019
In a paper recently published in Journal of the American Academy of Dermatology, researchers proposed there is a three-part pathogenesis of acute…

In the Journals

Alterations in pathway activation found in hidradenitis suppurativa

May 6, 2019
Biological pathways are disrupted among patients with hidradenitis suppurativa, which suggests that inflammatory pathways, pathways of leucocyte…

Meeting News

Dermatology pearls for the rheumatologist: cutaneous lupus, dermatomyositis

May 6, 2019
DESTIN, Fla. — In a session here at Congress of Clinical Rheumatology, Joseph F. Merola, MD, MMSc, of Harvard Medical School and Brigham and…

FDA News

FDA approves Skyrizi for moderate to severe plaque psoriasis

April 25, 2019
AbbVie announced that the FDA has approved Skyrizi, an interleukin-23 inhibitor for treating moderate to severe plaque psoriasis in adults who are…

In the Journals

Calcinosis linked to greater disease severity, duration in juvenile dermatomyositis

January 17, 2019
Among patients with juvenile dermatomyositis, calcinosis was associated with longer active disease duration, disease severity and clinical features…

FDA News

FDA awards $18 million to fund trials of medical products for rare diseases

September 29, 2018
The FDA awarded more than $18 million in grants over the next 4 years to fund clinical trials of medical products intended to treat patients with…

FDA News

FDA approves Rituxan for pemphigus vulgaris

June 8, 2018
The FDA has approved rituximab for the treatment of adult patients with moderate-to-severe pemphigus vulgaris, a rare autoimmune blistering disease…

Meeting News

IAS 2018: Advances, collaboration in immune-mediated inflammatory diseases

April 26, 2018
BOSTON — Rheumatologists, gastroenterologists, dermatologists, immunologists and other health care providers who care for patients with…

FDA News

FDA declines proposed Rituxan, Herceptin biosimilars from Celltrion

April 6, 2018
The FDA has rejected approval of Celltrion’s biologics license applications for Truxima, a proposed rituximab biosimilar, and Herzuma, a…

Healio Jobs